Vincerx Pharma (VINC) News Today → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free VINC Stock Alerts $0.72 -0.03 (-4.00%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 10:17 AM | msn.comVincerx Pharma GAAP EPS of -$0.58May 15 at 5:16 AM | finanznachrichten.deVincerx Pharma, Inc.: Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 14 at 11:06 PM | investorplace.comVINC Stock Earnings: Vincerx Pharma Misses EPS for Q1 2024May 14 at 4:15 PM | globenewswire.comVincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 26, 2024 | msn.comWhy Vincerx Pharma (VINC) Stock Is FallingApril 26, 2024 | globenewswire.comVincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and WarrantsApril 25, 2024 | globenewswire.comVincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and WarrantsApril 23, 2024 | nasdaq.comVincerx Pharma, Inc. Common Stock (VINC)April 12, 2024 | finance.yahoo.comAgendia’s BluePrint Included in German Oncology Group GuidelinesApril 10, 2024 | finance.yahoo.comThe Rise of Zyn: The Oral Nicotine Product Going ViralApril 10, 2024 | markets.businessinsider.comVincerx Pharma Inc (VINC) Gets a Buy from Leerink PartnersApril 9, 2024 | marketbeat.comTrading was temporarily halted for "VINC" at 09:04 AM with a stated reason of "LULD pause."April 9, 2024 | msn.comACOR, HUBC and DATS among pre-market losersApril 9, 2024 | msn.comVincerx in selloff after early-stage data for cancer therapyApril 9, 2024 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for Vincerx Pharma (NASDAQ:VINC)Cantor Fitzgerald reissued an "overweight" rating on shares of Vincerx Pharma in a report on Tuesday.April 9, 2024 | investorplace.comWhy Is Vincerx Pharma (VINC) Stock Down 64% Today?April 8, 2024 | globenewswire.comVincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024April 4, 2024 | marketbeat.comFY2024 EPS Estimates for Vincerx Pharma, Inc. Raised by Analyst (NASDAQ:VINC)Vincerx Pharma, Inc. (NASDAQ:VINC - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2024 EPS estimates for shares of Vincerx Pharma in a research report issued to clients and investors on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will postApril 3, 2024 | marketbeat.comQ1 2024 EPS Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC) Boosted by Leerink PartnrsVincerx Pharma, Inc. (NASDAQ:VINC - Free Report) - Analysts at Leerink Partnrs increased their Q1 2024 earnings per share (EPS) estimates for Vincerx Pharma in a report issued on Sunday, March 31st. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($0.April 2, 2024 | investorplace.comVINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023April 1, 2024 | finanznachrichten.deVincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateApril 1, 2024 | marketbeat.comVincerx Pharma (NASDAQ:VINC) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating on shares of Vincerx Pharma in a report on Monday.April 1, 2024 | finance.yahoo.comVincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024March 29, 2024 | finance.yahoo.comVincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close LookMarch 29, 2024 | marketwatch.comVincerx Pharma Cuts Funding-Sufficiency View to 3Q From Late 2024March 29, 2024 | globenewswire.comVincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateMarch 28, 2024 | marketbeat.comShort Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Expands By 95.2%Vincerx Pharma, Inc. (NASDAQ:VINC - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 863,700 shares, a growth of 95.2% from the February 29th total of 442,400 shares. Currently, 6.4% of the company's shares are sold short. Based on an average trading volume of 1,030,000 shares, the days-to-cover ratio is presently 0.8 days.March 25, 2024 | marketbeat.comVincerx Pharma (VINC) Set to Announce Earnings on TuesdayVincerx Pharma (NASDAQ:VINC) will be releasing earnings on Tuesday, March 26, Yahoo Finance reports.March 19, 2024 | edition.cnn.comVincerx Pharma IncMarch 12, 2024 | benzinga.comWhy Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionMarch 9, 2024 | marketbeat.comLeerink Partnrs Comments on Vincerx Pharma, Inc.'s Q1 2024 Earnings (NASDAQ:VINC)Vincerx Pharma, Inc. (NASDAQ:VINC - Free Report) - Analysts at Leerink Partnrs issued their Q1 2024 EPS estimates for Vincerx Pharma in a research note issued on Tuesday, March 5th. Leerink Partnrs analyst J. Chang anticipates that the company will post earnings per share of ($0.40) for the quartMarch 8, 2024 | marketbeat.comFY2024 EPS Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC) Reduced by Leerink PartnrsVincerx Pharma, Inc. (NASDAQ:VINC - Free Report) - Research analysts at Leerink Partnrs decreased their FY2024 earnings estimates for shares of Vincerx Pharma in a research report issued on Tuesday, March 5th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings ofMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vincerx Pharma Ahead of AACR Presentation: Promising Developments in Oncology Drug PipelineMarch 7, 2024 | marketbeat.comVincerx Pharma, Inc. to Post Q1 2024 Earnings of ($0.40) Per Share, Leerink Partnrs Forecasts (NASDAQ:VINC)Vincerx Pharma, Inc. (NASDAQ:VINC - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for Vincerx Pharma in a note issued to investors on Tuesday, March 5th. Leerink Partnrs analyst J. Chang forecasts that the company will earn ($0.40) pMarch 5, 2024 | globenewswire.comVincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024March 5, 2024 | finance.yahoo.comVincerx Pharma, Inc.'s (NASDAQ:VINC) large institutional owners must be happy as stock continues to impress, up 28% over the past weekFebruary 22, 2024 | morningstar.comVincerx Pharma Inc Ordinary Shares VINCFebruary 22, 2024 | benzinga.comVincerx Pharma Stock (NASDAQ:VINC) Dividends: History, Yield and DatesFebruary 21, 2024 | marketbeat.comTrading was temporarily halted for "VINC" at 10:02 AM with a stated reason of "LULD pause." Trading set to resume at 10:02 AM. January 10, 2024 | msn.comVincerx Pharma stock rises on positive efficacy data from lymphoma therapyJanuary 8, 2024 | msn.comWhy Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today?January 8, 2024 | marketwatch.comVincerx Pharma Shares Surge Following Early Results for Relapsed, Refractory LymphomaJanuary 8, 2024 | finanznachrichten.deVincerx Pharma, Inc.: Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in LymphomaJanuary 7, 2024 | finance.yahoo.comVincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in LymphomaNovember 14, 2023 | msn.comVincerx Pharma GAAP EPS of -$0.46November 14, 2023 | finanznachrichten.deVincerx Pharma, Inc.: Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 13, 2023 | finance.yahoo.comNew to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business NetworkSeptember 19, 2023 | finance.yahoo.comVincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023September 14, 2023 | finance.yahoo.comVincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943September 8, 2023 | benzinga.comDelveInsight Evaluates a Robust B-Cell Lymphoma Clinical Trial as 160+ Influential Pharma Companies to Set Foot in the 7MM Get Vincerx Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter. Email Address What’s Really Next for America… (Ad)Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly. Click here to stream this controversial exposé now. VINC Media Mentions By Week VINC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VINC News Sentiment▼-0.340.54▲Average Medical News Sentiment VINC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VINC Articles This Week▼61▲VINC Articles Average Week Get Vincerx Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INDP News Today NERV News Today NRSN News Today VBIV News Today AYTU News Today TLPH News Today ORGS News Today VAXX News Today APM News Today TNXP News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VINC) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsObama’s Forever Term [exposed]Porter & CompanyGold Set to EXPLODE!Gold Safe ExchangeThe 1,000X Crypto PlaybookTrue Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
